Brind.

Aligos Therapeutics is expanding its study abroad, gaining regulatory approvals in multiple countries including China, Moldova, Canada, Taiwan, and New Zealand.

1 report, 1 independent Updated Aug 7

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Aligos Therapeutics, Inc.Moldova China

Keep exploring

The entities involved

Aligos Therapeutics, Inc.
- Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma on August 20, 2025.Sun 04:59
Moldova
country in Eastern Europe
- Developments regarding Moldova's bid for EU membership, including seeking full bloc status amidst Russian interference.Mon 16:56
- The European Commission began leading accession talks with Ukraine and Moldova.Sun 23:53
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China
- The European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Mon 17:49
- The Middle Corridor, linking Central Asia and Europe, is gaining significance in regional trade and energy routes.Mon 17:06

Coverage

Newest first; wire copies grouped

Aug 7GlobeNewswireAligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS,